| 摘要 |
PROBLEM TO BE SOLVED: To provide combination therapies using histone deacetylase (HDAC) inhibitors as methods for treating cancer, such as lung cancer, multiple myeloma, lymphoma, and epithelial ovarian cancer.SOLUTION: A combination therapy using an HDAC inhibitor such as PXD-101 comprises administering a first amount or dose of the HDAC inhibitor and a second amount or dose of another chemotherapeutic agent, such as dexamethasone or 5-fluorouracil, or an epidermal growth factor receptor (EGFR) inhibitor, such as Tarceva(R), where the first and second amounts or doses comprise therapeutically effective amounts. The combined effect is greater than the additive effect resulting from administration of the two therapeutic agents each at a therapeutic dose. |
